Celldex Therapeutics Director Denice Torres Granted 26,000 Stock Options

This Form 4 filing reports that Denice Torres, a director of Celldex Therapeutics, Inc. (CLDX), was granted 26,000 non-qualified stock options on June 25, 2026. The options have an exercise price of $34.09 per share and vest on June 25, 2027, with an expiration date of June 25, 2036. The options were granted under the company's 2021 Omnibus Equity Incentive Plan. As a director, Torres received these options as part of her compensation package. The filing indicates direct ownership of these derivative securities. This transaction represents a standard equity compensation award to a board member, aligning her interests with shareholders through long-term incentive compensation tied to the company's stock performance.